Treatment of ovarian cancer with HO-3867 may be used as adjunctive therapy to improve outcomes in these patients.169 Another compound, andrographlide (ANDRO), was reported to suppress the expression of mutant p53 and promote the combination of the Hsp70 and mutant p53, further inducing proteasomal degradation of p53 and ultimately inhibiting cell growth.170. This evidence concerns the gene TP53 and ovarian carcinoma.